Not known Details About sodium phenobarbital solubility
Not known Details About sodium phenobarbital solubility
Blog Article
pentobarbital decreases effects of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers could reduce sufentanil ranges and efficacy, quite possibly precipitating withdrawal syndrome in sufferers who definitely have formulated physical dependence to sufentanil. Discontinuation of concomitantly used CYP3A4 inducers may well improve sufentanil plasma concentration.
pentobarbital will reduce the level or effect of conjugated estrogens by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Contraindicated (one)pentobarbital will lower the level or effect of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
Contraindicated (1)pentobarbital will reduce the level or effect of naloxegol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Usage of naloxegol with potent CYP3A4 inducers isn't suggested
pentobarbital will decrease the extent or effect of atorvastatin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will lessen the level or effect of ramelteon by impacting hepatic enzyme CYP2C9/10 metabolism. Insignificant/Significance Mysterious.
pentobarbital will reduce the level or effect of voriconazole by affecting hepatic enzyme CYP2C9/10 metabolism. Small/Significance Unfamiliar.
pentobarbital decreases levels of elvitegravir/cobicistat/emtricitabine/tenofovir DF by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May result in loss of check here virologic response and possible resistance.
pentobarbital will reduce the extent or effect of felodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will minimize the level or effect of apremilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration with robust CYP inducers brings about a major lessen of systemic publicity of apremilast, which can lead to loss of efficacy
pentobarbital will reduce the extent or effect of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a delicate CYP3A4 substrate. Coadministration with solid or reasonable CYP3A4 inducers is contraindicated.
Instead of prior executions, which used many drugs for lethal injection, federal executions will only use a single drug: pentobarbital. Some states have by now used the chemical for executions including Texas, Missouri and Georgia.
pentobarbital will decrease the extent or effect of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will decrease the level or effect of dutasteride by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.